Breast Cancer Clinical Trial
Official title:
Dynamic Infrared Thermography in Breast Cancer Diagnostics. A Diagnostic Accuracy Study Comparing Dynamic Infrared Thermography Against Mammography (Reference Standard)
This study evaluate diagnostic accuracy of dynamic infrared thermography compared to mammography (reference test) in breast cancer diagnostics. Women aged 50-70 years, selected for assessment after mammography screening were invited to dynamic infrared thermography before clinical mammography and further examination.
This study evaluate diagnostic accuracy of dynamic infrared thermography compared to
mammography (reference test) in breast cancer diagnostics.
Dynamic infrared thermography (DIRT) is an imagine procedure offering a non-invasive,
painless examination without risk of radiation. Dynamic infrared thermography does not
provide information on the morphological characteristics of the breast, rather it provides
functional information on thermal and vascular conditions of the tissue (Fitzgerald, 2012).
During the study period from April 2009 until June 2012, a total of 168 women aged 50-70
years who were recalled for assessment after positive mammography screening were offered
dynamic infrared thermography before further tests (clinical mammography, clinical
examination and if necessary breast tissue biopsy).
Radiographers at the Breast Diagnostic Center (BDS) at University Hospital North Norway
collected information about parity, menopausal status, use of hormone therapy and size of
bra.
The same radiographers also carried out all the dynamic infrared thermography examinations.
PI Åshild O. Miland and Professor James B. Mercer interpreted the thermograms and entered
the data into the thermography database. Both were blinded for further assessments
(mammography, clinical examination and biopsy) and non of them talked to any of the
participants after the examination.
The health professionals who were responsible for the women during mammography, clinical
examination and biopsy were blinded for the results from the infrared digital thermography
examination. They were not allowed to ask the women about the infrared digital thermography
examination.
The three radiologists at BDS made the interpretation of the mammographies and entered data
into the digital patient journal and to the mammography database at The Norwegian Cancer
Registry. One of the radiologist took, when necessary, breast biopsies. A breast surgeons
were responsible for the clinical breast examination. Pathologists verified the histology.
Breast radiologist Jan Ole Frantzen and researcher Merethe Kumle, MD, PhD collected
information about breast cancer results from the digital patient journal and Roentgen
information system (RIS) and entered it into a separate mammography database.
The thermography database and the mammography database was still not merged at the time of
registration in ClinicalTrials.gov (March 2015).
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |